Xentria, a Chicago, IL-based biotech company, raised $25M in Equity funding.
The backers were not disclosed.
The company intends to use the funds to further strengthen the depth of its scientific and technical leadership and drive the clinical development process forward. Funds will also support next stage clinical development of XTMAB-16, including the launch of a global clinical trial in sarcoidosis expected to initiate in early 2023.
Founded in 2020 and Kirsten Anderson, Chief Operating Officer, Xentria is is an innovative biopharmaceutics company whose primary focus is to build an expansive product pipeline of therapeutics to address critical unmet need for patients suffering from rare diseases, immunologic disorders and oncological conditions. Its lead candidate, XTMAB-16 a chimeric monoclonal antibody being evaluated as a potential therapy for patients with sarcoidosis, a chronic, multisystem inflammatory disorder.
FinSMEs
18/10/2022